Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00577473 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)
A Phase 3 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 3
- Development phase
- 301
- Enrollment target
NCT00577473 is a Phase 3 study that has completed, run by Warner Chilcott. The registered enrollment target is 301 participants.
The verdict
NCT00577473, a Phase 3 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 301 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of Asacol 4.8 g/day (800 mg tablet) versus Asacol 2.4 g/day (400 mg tablet
Interventions
- DRUG mesalamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2001-02 |
| Est. Completion | 2003-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00577473
The ClinicalTrials.gov registry entry for NCT00577473 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which mesalamine is the first listed.
NCT00577473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00577473 about?
NCT00577473 is a clinical study titled "Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)". The purpose of this study is to evaluate the safety and efficacy of Asacol 4.8 g/day (800 mg tablet) versus Asacol 2.4 g/day (400 mg tablet
What is the current status of trial NCT00577473?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 301 participants. The study started on 2001-02. Estimated completion is 2003-02.
What interventions are being tested in trial NCT00577473?
The interventions under investigation include: mesalamine (DRUG).
Who is sponsoring clinical trial NCT00577473?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.